COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER

被引：1

作者：

Tikhonova, I ^{[1
]}

Hoyle, M. ^{[1
]}

Snowsill, T. ^{[1
]}

Crathorne, L. ^{[1
]}

Varley-Campbell, J. ^{[1
]}

Peters, J. ^{[1
]}

Briscoe, S. ^{[1
]}

Bond, M. ^{[1
]}

Huxley, N. ^{[1
]}

机构：

[1] Univ Exeter, Exeter, Devon, England

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 03期

关键词：

D O I：

10.1016/j.jval.2016.03.1612

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN113

引用

页码：A154 / A154

页数：1

共 50 条

[41] Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making
Franken, Mira D.
Koopman, Miriam
van Oijen, Martijn G. H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (02): : 214 - 214
[42] COST-EFFECTIVENES OF CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER IN BELGIUM AND THE NETHERLANDS
Krol, M.
Ovcinnikova, O.
von Hohnhorst, P.
Jarrett, J.
VALUE IN HEALTH, 2015, 18 (07) : A464 - A464
[43] Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.
Zhang, Yanqiao
Zheng, Tongsen
Liu, Maobai
Li, Te
Wu, Bin
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[44] Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
Hannouf, Malek B.
Sehgal, Chander
Cao, Jeffrey Q.
Mocanu, Joseph D.
Winquist, Eric
Zaric, Gregory S.
PLOS ONE, 2012, 7 (06):
[45] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
Attard, Cheryl L.
Brown, Stephen
Alloul, Karine
Moore, Malcolm J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[46] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
Souza, P., V
Zanini, F. E.
Biglia, L., V
Kim, H. S.
Fahham, L.
VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
[47] COST-EFFECTIVENESS OF CETUXIMAB VERSUS PANITUMUMAB IN THIRD-LINE THERAPY FOR CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER IN BRAZIL
Sasse, Andre
Carvalho, Adriana
ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
[48] Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
Gerard Harty
James Jarrett
Mireia Jofre-Bonet
Applied Health Economics and Health Policy, 2018, 16 : 515 - 525
[49] Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
Harty, Gerard
Jarrett, James
Jofre-Bonet, Mireia
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 515 - 525
[50] Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
Tsai, Hsiang-Lin
Wang, Jaw-Yuan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 38 - 38

← 1 2 3 4 5 →